ATRSのチャート
ATRSの企業情報
| symbol | ATRS |
|---|---|
| 会社名 | Antares Pharma Inc. （アンタレス・ファ―マ） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Medical/Dental Instruments |
| 業種 | 医療機器_医療用品_ディストリビュ―タ― 医療関連（Health Care） |
| 概要 | 事業概要 アンタレス・ファーマ(Antares Pharma Inc.)は自己投与される非経口医薬品および技術の開発・商業化に従事する専門医薬品会社である。同社は患者が薬物を自己注射することを可能にするニードル有り・無しの圧力補助式注射器を開発・製造する。同社の皮下注射技術プラットフォームは、VIBEX使い捨て圧力支援自動インジェクタ、Vision再使用可能な無針注射器、及び使い捨ての多目的ペンインジェクタを含む。同社は薬物送達事業セグメントを通じて運営する。薬物送達事業は自己投与される非経口医薬品および技術を含む。同社は単回用量の使い捨て自動注射器であるOTREXUP（メトトレキセート）注射剤を開発した。 アンタレス・ファ―マは、米国の医薬品メ―カ―。無針・微小針の注射システムや経皮ジェルなどの薬品送達システムを開発、製造、販売する。主な商品は、関節リウマチに対するメトトレキサ―トの皮下注製剤｢OTREXUP｣、自己注製剤｢Medi-Jet｣、使い捨て可能な自動注入器｢Vibex｣など。本社は、ニュ―ジャ―ジ―州イウィング。 Antares Pharma, Inc. is a pharmaceutical technology company focused primarily on the development and commercialization of self-administered injectable pharmaceutical products using advanced drug delivery auto injector technology. The Company has a portfolio of proprietary and partnered commercial products with several product candidates in various stages of development, as well as significant strategic alliances with industry leading pharmaceutical companies including Teva Pharmaceutical Industries, Ltd. (Teva), Covis Pharma (Covis), Pfizer Inc. (Pfizer) and Idorsia Pharmaceuticals Ltd. (Idorsia). Antares Pharma's FDA-approved products include XYOSTED® (testosterone enanthate) injection, OTREXUP® (methotrexate) injection for subcutaneous use and Sumatriptan Injection USP, which is distributed by Teva. The Company also markets NOCDURNA® (desmopressin acetate) in the U.S., which was licensed from Ferring Pharmaceuticals. |
| 本社所在地 | 100 Princeton South Suite 300 Ewing NJ 08628 USA |
| 代表者氏名 | Leonard S. Jacob レオナルドS.ジェイコブ |
| 代表者役職名 | Independent Chairman of the Board |
| 電話番号 | +1 609-359-3020 |
| 設立年月日 | 1979年 |
| 市場名 | NASDAQ Small Cap |
| ipoyear | ―年 |
| 従業員数 | 111人 |
| url | www.antarespharma.com |
| nasdaq_url | https://www.nasdaq.com/symbol/atrs |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -16.15604 |
| 終値（lastsale） | 3.75 |
| 時価総額（marketcap） | 590387628.75 |
| 時価総額 | 時価総額（百万ドル） 573.06960 |
| 売上高 | 売上高（百万ドル） 55.95639 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 569.27960 |
| 当期純利益 | 当期純利益（百万ドル） -19.88014 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Antares Pharma Inc revenues increased 6% to $26.9M. Net loss increased 41% to $10.7M. Revenues reflect Europe segment increase of 42% to $3.2M United States of America segment increase of 3% to $23.4M. Higher net loss reflects Research and development increase of 12% to $7M (expense) Selling general and administrative increase of 3% to $15.3M (expense). |
ATRSのテクニカル分析
ATRSのニュース
Halozyme: Antares Pharma Bolsters Growth Prospects 2022/05/19 09:41:10 Seeking Alpha
Halozyme announced acquisition of Antares Pharma at $5.60 per share in cash. See why I expect to have a position in HALO stock for at least five more years.
ANTARES PHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Antares Pharma, Inc. - ATRS 2022/04/26 01:33:00 Business Wire
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Antares Pharma, Inc. (NasdaqCM: ATRS) to Halozyme Therapeutics, Inc. (NasdaqGS: HALO). Under the terms of the proposed transaction, shareholders of Antares will receive only $5.60 in cash for each share of Antares that they own. KSF is seeking to determine whether this consideration and the process that led to
SHAREHOLDER ALERT: Weiss Law Reminds ATRS, SRRA, HBP, and EMCF Shareholders About Its Ongoing Investigations 2022/04/20 17:54:00 Benzinga
NEW YORK , April 20, 2022 /PRNewswire/ -- If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights or interests, please contact: Joshua Rubin, Esq. Weiss Law 305 Broadway, 7th Floor New York, NY 10007 (212) 682-3025 (888) 593-4771 stockinfo@weisslawllp.com Antares Pharma, Inc. … Full story available on Benzinga.com
Hot Stock’s Watch List: Antares Pharma, Inc. (NASDAQ:ATRS), Occidental Petroleum Corporation (NYSE:OXY) 2022/04/15 14:59:34 Stock Equity
Antares Pharma, Inc. (NASDAQ:ATRS) with the stream of -0.36% also noticed, India Occidental Petroleum Corporation (NYSE:OXY) encountered a rapid change of -0.47% in the last hour of Friday’s trading session. … The post Hot Stock’s Watch List: Antares Pharma, Inc. (NASDAQ:ATRS), Occidental Petroleum Corporation (NYSE:OXY) appeared first on Stocks Equity .
Vamping stocks: Antares Pharma, Inc. (NASDAQ:ATRS -0.36%), New Oriental Education & Technology Group Inc. (NYSE:EDU -1.77%) 2022/04/14 23:18:32 Stock Equity
There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well have a look on, SMA50 … The post Vamping stocks: Antares Pharma, Inc. (NASDAQ:ATRS -0.36%), New Oriental Education & Technology Group Inc. (NYSE:EDU -1.77%) appeared first on Stocks Equity .
Halozyme: Antares Pharma Bolsters Growth Prospects 2022/05/19 09:41:10 Seeking Alpha
Halozyme announced acquisition of Antares Pharma at $5.60 per share in cash. See why I expect to have a position in HALO stock for at least five more years.
ANTARES PHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Antares Pharma, Inc. - ATRS 2022/04/26 01:33:00 Business Wire
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Antares Pharma, Inc. (NasdaqCM: ATRS) to Halozyme Therapeutics, Inc. (NasdaqGS: HALO). Under the terms of the proposed transaction, shareholders of Antares will receive only $5.60 in cash for each share of Antares that they own. KSF is seeking to determine whether this consideration and the process that led to
SHAREHOLDER ALERT: Weiss Law Reminds ATRS, SRRA, HBP, and EMCF Shareholders About Its Ongoing Investigations 2022/04/20 17:54:00 Benzinga
NEW YORK , April 20, 2022 /PRNewswire/ -- If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights or interests, please contact: Joshua Rubin, Esq. Weiss Law 305 Broadway, 7th Floor New York, NY 10007 (212) 682-3025 (888) 593-4771 stockinfo@weisslawllp.com Antares Pharma, Inc. … Full story available on Benzinga.com
Hot Stock’s Watch List: Antares Pharma, Inc. (NASDAQ:ATRS), Occidental Petroleum Corporation (NYSE:OXY) 2022/04/15 14:59:34 Stock Equity
Antares Pharma, Inc. (NASDAQ:ATRS) with the stream of -0.36% also noticed, India Occidental Petroleum Corporation (NYSE:OXY) encountered a rapid change of -0.47% in the last hour of Friday’s trading session. … The post Hot Stock’s Watch List: Antares Pharma, Inc. (NASDAQ:ATRS), Occidental Petroleum Corporation (NYSE:OXY) appeared first on Stocks Equity .
Vamping stocks: Antares Pharma, Inc. (NASDAQ:ATRS -0.36%), New Oriental Education & Technology Group Inc. (NYSE:EDU -1.77%) 2022/04/14 23:18:32 Stock Equity
There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well have a look on, SMA50 … The post Vamping stocks: Antares Pharma, Inc. (NASDAQ:ATRS -0.36%), New Oriental Education & Technology Group Inc. (NYSE:EDU -1.77%) appeared first on Stocks Equity .
Antares Pharma to Present at the Cowen 42nd Annual Healthcare Conference 2022/02/28 13:30:00 GlobeNewswire
EWING, N.J., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (the “Company”), a specialty pharmaceutical company, today announced that Robert F. Apple, President and Chief Executive Officer, is scheduled to virtually present and host investor meetings at the Cowen 42 nd Annual Healthcare Conference being held on March 7-9, 2022.
Antares Pharma Inc. (NASDAQ: ATRS) Is Up 4.18% In A Month. Could There Be Any Hope That It Will Rise Soon? 2022/02/19 15:30:00 Marketing Sentinel
During the last session, Antares Pharma Inc. (NASDAQ:ATRS)s traded shares were 0.46 million, with the beta value of the company hitting 1.49. At the end of the trading day, the stocks price was $3.49, reflecting an intraday loss of -2.51% or -$0.09. The 52-week high for the ATRS share is $5.07, that puts it down Antares Pharma Inc. (NASDAQ: ATRS) Is Up 4.18% In A Month. Could There Be Any Hope That It Will Rise Soon? Read More »
Antares Pharma To Report Fourth Quarter And Full-Year 2021 Financial And Operating Results 2022/02/17 13:30:00 GlobeNewswire
EWING, N.J., Feb. 17, 2022 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (the “Company”), a specialty pharmaceutical company, today announced it will release its fourth quarter and full-year 2021 financial and operating results on Thursday, March 3, 2022, before the market opens.